IFM Therapeutics ‘Lather, Rinse, Repeat’ Strategy On Track With $55M Financing
Executive Summary
The drug discovery company with a big pharma deal-making track record is launching a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery. Scrip talked to IFM's new CEO Martin Seidel about what is ahead for the company.
You may also be interested in...
Novartis' Drug Discovery Head Jay Bradner On What NIBR Is Investing In
NIBR's Bradner talked to Scrip about how AveXis turbo-charged Novartis' gene therapy development, investing in inflammasome research, and partnering nimbly like a venture capitalist.
Novartis Dives Into Inflammasome Pool With IFM Tre Purchase
The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports